Bausch & Lomb, Arrow shareholders approve buy-out offers:
This article was originally published in Clinica
Warburg Pincus has won over Bausch & Lomb's shareholders, who last week approved the private equity firm's $65-per-share all cash offer to buy the eye care company. Over two thirds of the total shares were voted in favour of the transaction, which is expected to close early in the fourth quarter of 2007. Another merger deal poised to close is Teleflex's $2bn acquisition of Arrow International. Arrow shareholders gave their blessing to the transaction, and voted to re-elect all of Arrow's existing board directors. The deal is slated to close on October 1.
You may also be interested in...
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.
US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.